Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704547 | 0.98 | PDE4A (0.57) | PDE4APDE4BPDE4DPDE4CMAPK14 | |
| SCHEMBL7450822 | 0.87 | PDE4A (0.71) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL13459865 | 0.84 | DRD2 (0.46) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL6798284 | 0.84 | PDE4A (0.65) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL8793190 | 0.82 | PDE4B (0.46) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL5823060 | 0.82 | PDE4A (0.77) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL24749771 | 0.82 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CMAPK14 | |
| SCHEMBL31694801 | 0.82 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CMAPK14 | |
| SCHEMBL28581404 | 0.82 | PDE4B (0.50) | PDE4APDE4BPDE4DPDE4CMAPK14 | |
| SCHEMBL24749768 | 0.82 | PDE4A (0.43) | PDE4APDE4BPDE4DPDE4CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110526856-B | Synthetic method of DWP205190 | 天津瑞岭化工有限公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2008022060-A2 | IMIDAZO-PYRIDINE DERIVATIVES FOR MODULATING PROTEIN KINASE ACTIVITY | NOVARTIS AG (CH) | 2008-02-21 | — | — | WO | claimed |
| JP-11189577-A | — | — | None | — | — | JP | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-110526856-B | Synthetic method of DWP205190 | 天津瑞岭化工有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-3774739-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RaQualia Pharma Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019198692-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2019-10-17 | — | — | WO | disclosed |
| WO-1996036595-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| US-5550137-A | Phenylaminocarbonyl derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| EP-0607373-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS. | CELLTECH LTD (GB) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
| WO-1993025517-A1 | TRISUBSTITUTED PHENYL DERIVATIVES AS SELECTIVE PHOSPHODIESTERASE IV INHIBITORS | CELLTECH LIMITED (GB) | 1993-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | PDE4A 733/4885PDE4B 793/4885PDE4D 1521/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | PDE4A 733/4885PDE4B 793/4885PDE4D 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.